---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-112949"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2025-09-04T23:59:59+00:00"
generated_at: "2026-05-17T08:20:29.980621+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "medium"
source: SEC EDGAR
---

# Cullinan Therapeutics revises CLN-978 SLE data timing to H1 2026

## Summary
- Initial clinical data for CLN-978 in systemic lupus erythematosus now expected in first half of 2026.
- Timelines for all other pipeline programs remain unchanged.
- Updated corporate presentation posted to company website; no other changes disclosed in filing.

## SEC filing metadata
- accession: 0000950170-25-112949
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2025-09-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: medium
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000095017025112949/0000950170-25-112949-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000095017025112949/cgem-20250904.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-112949
- JSON: https://secwatch.observer/filing/0000950170-25-112949.json
- Plain text: https://secwatch.observer/filing/0000950170-25-112949.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.